As investments in India is boosted in line with Make in India campaign, the global giant of medical devices, pharmaceuticals, consumer healthcare Johnson & Johnson to double its annual production capacity, is set to invest another Rs. 650crore ($100 million) for its plant in Telangana near Hyderabad. Earlier J & J has invested Rs. 550 crore for its India’s largest upcoming facility which would produce 18000 tons baby care, skin care and personal hygiene products. Currently, J & J have two manufacturing plants, one in Mumbai and another in Baddi. The Stay Free brand for feminine hygiene and Listerine brand for oral care is witnessing robust growth. READ ALSO: How to get a manufacturing License in India.
With lots of innovative measures in water consumption, energy efficiency, waste management the Telangana J & J facility is coming up and with additional product lines with this expansion. With the south Indian market accounting for more than one third of its Indian business, the manufacturing facility will be able to deliver its growth of business over the region. The work for making the production double would start in a quarter said an official from J & J.
Other News
CDSCO Issues Guidelines on Medical Device License Retention
New Delhi, May 15, 2024 — The Central Drugs Standard Control Organization (CDSCO) has released a circular (F. No. MED-15/35/2024-eOffice) on the retention of medical device licenses and certificates under the Medical Devices Rules, 2017. […]
Read MoreIndia Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More